Caspase Inhibitors for the Treatment of Hepatitis C

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 467-475

  Masuoka, Howard C ^a   Guicciardi, Maria Eugenia ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Caspase inhibitors; Death receptors; Hepatic fibrogenesis; Hepatitis C; Nonalcoholic steatohepatitis

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; COLLAGEN TYPE 1; CYSTEINE PROTEINASE; CYTOKERATIN 18; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 1; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CLINICAL TRIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER INJURY; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

AMINO ACID CHLOROMETHYL KETONES; ANTIVIRAL AGENTS; APOPTOSIS; CASPASES; CYSTEINE PROTEINASE INHIBITORS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS;

EID: 67650552582     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.010     Document Type: Review

References (48)

1. Canbay A., Taimr P., Torok N., et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83 5 (2003) 655-663
2. Canbay A., Feldstein A.E., Higuchi H., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38 5 (2003) 1188-1198
3. Canbay A., Friedman S., and Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 2 (2004) 273-278
4. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 5381 (1998) 1312-1316
5. Zender L., Hutker S., Liedtke C., et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 100 13 (2003) 7797-7802
6. Kaufmann T., Jost P.J., Pellegrini M., et al. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity 30 1 (2009) 56-66
7. Chen J., Nagayama T., Jin K., et al. Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J Neurosci 18 13 (1998) 4914-4928
8. Strobel T., Swanson L., Korsmeyer S., et al. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 93 24 (1996) 14094-14099
9. Adachi M., Suematsu S., Kondo T., et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 11 3 (1995) 294-300
10. Pfeffer K., Matsuyama T., Kundig T.M., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 3 (1993) 457-467
11. Yue H.H., Diehl G.E., and Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 12 1 (2005) 94-97
12. Nakamoto Y., Kaneko S., Fan H., et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 196 8 (2002) 1105-1111
13. Calabrese F., Pontisso P., Pettenazzo E., et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 31 5 (2000) 1153-1159
14. Kountouras J., Zavos C., and Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat 10 5 (2003) 335-342
15. Mengshol J.A., Golden-Mason L., and Rosen H.R. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 4 11 (2007) 622-634
16. Bantel H., Lugering A., Heidemann J., et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40 5 (2004) 1078-1087
17. Bantel H., Lugering A., Poremba C., et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34 4 Pt 1 (2001) 758-767
18. Volkmann X., Fischer U., Bahr M.J., et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46 5 (2007) 1498-1508
19. Hayashi N., and Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat 6 5 (1999) 357-365
20. Mochizuki K., Hayashi N., Hiramatsu N., et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 24 1 (1996) 1-7
21. Luo K.X., Zhu Y.F., Zhang L.X., et al. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J Viral Hepat 4 5 (1997) 303-307
22. Galle P.R., Hofmann W.J., Walczak H., et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182 5 (1995) 1223-1230
23. Hiramatsu N., Hayashi N., Katayama K., et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19 6 (1994) 1354-1359
24. Yoneyama K., Goto T., Miura K., et al. The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res 24 4 (2002) 327-337
25. Ando K., Hiroishi K., Kaneko T., et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 158 11 (1997) 5283-5291
26. Gonzalez-Amaro R., Garcia-Monzon C., Garcia-Buey L., et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 179 3 (1994) 841-848
27. Bantel H., and Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 10 Suppl 1 (2003) S48-S58
28. Tokushige K., Yamaguchi N., Ikeda I., et al. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am J Gastroenterol 95 8 (2000) 2040-2046
29. Mundt B., Kuhnel F., Zender L., et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 17 1 (2003) 94-96
30. Lan L., Gorke S., Rau S.J., et al. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol 181 7 (2008) 4926-4935
31. Zheng S.J., Wang P., Tsabary G., et al. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113 1 (2004) 58-64
32. Piekarska A., Kubiak R., Omulecka A., et al. Expression of tumour necrosis factor-related apoptosis-inducing ligand and caspase-3 in relation to grade of inflammation and stage of fibrosis in chronic hepatitis C. Histopathology 51 5 (2007) 597-604
33. Mundt B., Wirth T., Zender L., et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54 11 (2005) 1590-1596
34. Fischer R., Baumert T., and Blum H.E. Hepatitis C virus infection and apoptosis. World J Gastroenterol 13 36 (2007) 4865-4872
35. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 309 5734 (2005) 623-626
36. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 7 (2005) 791-796
37. Chou A.H., Tsai H.F., Wu Y.Y., et al. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 174 4 (2005) 2160-2166
38. Radziewicz H., Ibegbu C.C., Hon H., et al. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J Virol 82 20 (2008) 9808-9822
39. Radziewicz H., Ibegbu C.C., Fernandez M.L., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 81 6 (2007) 2545-2553
40. Toubi E., Kessel A., Goldstein L., et al. Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J Hepatol 35 6 (2001) 774-780
41. Yoshida N., Iwata H., Yamada T., et al. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis by caspase inhibitor. J Gastroenterol Hepatol 22 11 (2007) 2015-2021
42. Natori S., Selzner M., Valentino K.L., et al. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 68 1 (1999) 89-96
43. Natori S., Higuchi H., Contreras P., et al. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl 9 3 (2003) 278-284
44. Hoglen N.C., Anselmo D.M., Katori M., et al. A caspase inhibitor IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl 13 3 (2007) 361-366
45. Hoglen N.C., Chen L.S., Fisher C.D., et al. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther 309 2 (2004) 634-640
46. Canbay A., Feldstein A., Baskin-Bey E., et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308 3 (2004) 1191-1196
47. Pockros P.J., Schiff E.R., Shiffman M.L., et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46 2 (2007) 324-329
48. Baskin-Bey E.S., Washburn K., Feng S., et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 7 1 (2007) 218-225